Bone structure and remodelling in stroke patients: early effects of zoledronate

Kenneth E S Poole, Shobna Vedi, Irene Debiram, Collette Rose, Jon Power, Nigel Loveridge, Elizabeth A Warburton, Jonathan Reeve, Juliet Compston, Kenneth E S Poole, Shobna Vedi, Irene Debiram, Collette Rose, Jon Power, Nigel Loveridge, Elizabeth A Warburton, Jonathan Reeve, Juliet Compston

Abstract

Introduction: We have reported that after an acute stroke, intravenous zoledronate prevented bone loss in the hemiplegic hip. Participants from the trial also volunteered for trans-iliac bone biopsy, to assess the early effects of stroke and zoledronate on iliac bone remodelling.

Methods: Patients with acute stroke were randomly assigned to a single intravenous dose of zoledronate 4 mg or placebo within 5 weeks of stroke. Biopsies from 14 patients (3 female, 11 male, mean age 71+/-11) were suitable for analysis. These were taken at mean 10 weeks (+/-2) post-stroke, and included 5 patients who had received zoledronate. Histomorphometry was performed on undecalcified sections using light and fluorescence microscopy. Static and dynamic indices of remodelling were compared to a local reference range from healthy controls. Osteoclasts and their precursors were identified on frozen sections using tartrate resistant acid phosphatase (TRAP) staining. Dual-energy x-ray absorptiometry (DXA) of the proximal femora was performed at baseline and 6 months later.

Results: The eroded surface in cancellous bone (ES/BS) was significantly higher in stroke patients than controls (5.7% vs. ref 1.6%, p<0.0001). Although ES/BS did not differ between zoledronate and placebo-treated groups, there were significantly fewer osteoclasts and their precursors in zoledronate-treated individuals (p=0.023). Bone formation indices (osteoid surface, OS/BS and mineralising surface, MS/BS) were significantly lower in stroke patients than controls and although OS/BS was higher in the zoledronate group than the placebo group (p=0.033), MS/BS was not different (p=0.924). There were no differences between hemiplegic and unaffected sides for any histomorphometric parameter despite asymmetric reductions in hip bone mineral density (p=0.013).

Conclusion: Stroke patients had higher resorption indices and lower bone forming surfaces than controls, consistent with uncoupling of bone remodelling. These findings are preliminary and a larger study is required to evaluate the contributions of gender, age and hemiplegic status to the remodelling imbalance. Zoledronate therapy was associated with a reduction in osteoclastic cell numbers consistent with its known mode of action in bone.

References

    1. Poole K.E., Loveridge N., Rose C.M., Warburton E.A., Reeve J. A single infusion of zoledronate prevents bone loss after stroke. Stroke. 2007;38:1519–1525.
    1. Sato Y., Kuno H., Kaji M., Etoh K., Oizumi K. Influence of immobilization upon calcium metabolism in the week following hemiplegic stroke. J. Neurol. Sci. 2000;175:135–139.
    1. Sato Y., Kuno H., Kaji M., Ohshima Y., Asoh T., Oizumi K. Increased bone resorption during the first year after stroke. Stroke. 1998;29:1373–1377.
    1. Sato Y., Iwamoto J., Kanoko T., Satoh K. Risedronate therapy for prevention of hip fracture after stroke in elderly women. Neurology. 2005;64:811–816.
    1. Jorgensen L., Jacobsen B.K., Wilsgaard T., Magnus J.H. Walking after stroke: does it matter? Changes in bone mineral density within the first 12 months after stroke. A longitudinal study. Osteoporos. Int. 2000;11:381–387.
    1. Sato Y., Kaji M., Saruwatari N., Oizumi K. Hemiosteoporosis following stroke: importance of pathophysiologic understanding and histologic evidence. Stroke. 1999;30:1978–1979.
    1. Poole K.E., Loveridge N., Barker P.J. Reduced vitamin D in acute stroke. Stroke. 2006;37:243–245.
    1. Sato Y., Asoh T., Kaji M., Oizumi K. Beneficial effect of intermittent cyclical etidronate therapy in hemiplegic patients following an acute stroke. J. Bone Miner. Res. 2000;15:2487–2494.
    1. Mahoney F., Barthel D. Functional evaluation: the Barthel Index. Maryland State Med. J. 1965;14:56–61.
    1. Scandinavian Stroke Study Group Multicenter trial of hemodilution in ischemic stroke—background and study protocol. Stroke. 1985;16:885–890.
    1. Frost H.M. Tetracycline-based histological analysis of bone remodeling. Calcif. Tissue Res. 1969;3:211–237.
    1. Poole K.E., van Bezooijen R.L., Loveridge N. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. Faseb J. 2005;19:1842–1844.
    1. Farquharson C., Whitehead C., Rennie S., Thorp B., Loveridge N. Cell proliferation and enzyme activities associated with the development of avian tibial dyschondroplasia: an in situ biochemical study. Bone. 1992;13:59–67.
    1. Vedi S., Compston J.E., Webb A., Tighe J.R. Histomorphometric analysis of bone biopsies from the iliac crest of normal British subjects. Metab. Bone Dis. Relat. Res. 1982;4:231–236.
    1. Garrahan N.J., Mellish R.W.E., Compston J.E. A new method for the analysis of two-dimensional trabecular bone structure in human iliac crest biopsies. J. Microsc. 1986;142:341–349.
    1. Freemont A.J. Bone histomorphometry. In: Tovey F.I., Stamp T.C.B., editors. The measurement of metabolic bone disease. Parthenon Publishing Group Ltd; 1995. pp. 77–90.
    1. Foldes J., Shih M.S., Parfitt A.M. Frequency distributions of tetracycline-based measurements: implications for the interpretation of bone formation indices in the absence of double-labeled surfaces. J. Bone Miner. Res. 1990;5:1063–1067.
    1. Kragstrup J., Gundersen H.J., Melsen F., Mosekilde L. Estimation of the three-dimensional wall thickness of completed remodeling sites in iliac trabecular bone. Metab. Bone Dis. Relat. Res. 1982;4:113–119.
    1. Parfitt A.M., Drezner M.K., Glorieux F.H. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner. Res. 1987;2:595–610.
    1. Parfitt A.M. The physiologic and clinical significance of bone histomorphometric data. In: RR R, editor. Bone Histomorphometry. CRC Press; London: 1983. pp. 143–223.
    1. Recker R.R., Delmas P.D., Halse J. The effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J. Bone Miner. Res. 2007
    1. Ramnemark A., Nyberg L., Lorentzon R., Englund U., Gustafson Y. Progressive hemiosteoporosis on the paretic side and increased bone mineral density in the nonparetic arm the first year after severe stroke. Osteoporos. Int. 1999;9:269–275.
    1. Poole K.E., Reeve J., Warburton E.A. Falls, fractures, and osteoporosis after stroke: time to think about protection? Stroke. 2002;33:1432–1436.
    1. Poole K.E.S., Warburton E.A., Reeve J. Rapid long-term bone loss following stroke in a man with osteoporosis and atherosclerosis. Osteoporos. Int. 2005;16:302–305.
    1. Sato Y., Kaji M., Honda Y. Abnormal calcium homeostasis in disabled stroke patients with low 25-hydroxyvitamin D. Bone. 2004;34:710–715.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다